AGC will assume technology transfer and feasibility study for drug product for the treatment of Idiopathic pulmonary fibrosis at its Cell & Gene CoE in Milan.
The two parties plan to collaborate to introduce more high-quality innovative drugs into Southeast Asian markets to achieve joint and long-term development.
The collaboration has allowed ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells to treat cancer.
Project will provide a four-fold increase in gene therapy process development and analytical capacity accommodating viral vector, DNA and RNA drug substance.